Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Adaptimmune Therapeutics stock
Learn how to easily invest in Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics Plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 494 staff and has a trailing 12-month revenue of around $11.7 million.
How to buy shares in Adaptimmune Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ADAP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Adaptimmune Therapeutics stock price (NASDAQ: ADAP)Use our graph to track the performance of ADAP stocks over time.
Adaptimmune Therapeutics shares at a glance
|Latest market close||$1.08|
|52-week range||$1.01 - $5.95|
|50-day moving average||$1.86|
|200-day moving average||$2.19|
|Wall St. target price||$5.83|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.09|
Buy Adaptimmune Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Adaptimmune Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adaptimmune Therapeutics price performance over time
|1 week (2022-09-27)||-3.15%|
|1 month (2022-09-02)||-46.78%|
|3 months (2022-07-01)||-34.85%|
|6 months (2022-03-31)||N/A|
|1 year (2021-09-30)||-79.21%|
|2 years (2020-10-02)||-86.58%|
|3 years (2019-10-04)||1.22|
|5 years (2017-10-04)||8.74|
Is Adaptimmune Therapeutics stock undervalued or overvalued?
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's PEG ratio
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Adaptimmune Therapeutics financials
|Revenue TTM||$11.7 million|
|Gross profit TTM||$-104,941,000|
|Return on assets TTM||-28.72%|
|Return on equity TTM||-83.86%|
|Market capitalisation||$175.6 million|
TTM: trailing 12 months
Adaptimmune Therapeutics share dividends
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Adaptimmune Therapeutics share price volatility
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $1.01 up to $5.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 1.7539. This would suggest that Adaptimmune Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc. , Alpine Immune Sciences, Inc. , and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc.
Adaptimmune Therapeutics in the news
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adaptimmune Therapeutics plc - ADAP
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Frequently asked questionsWhat percentage of Adaptimmune Therapeutics is owned by insiders or institutions?
Currently 0.172% of Adaptimmune Therapeutics shares are held by insiders and 70.913% by institutions. How many people work for Adaptimmune Therapeutics?
Latest data suggests 494 work at Adaptimmune Therapeutics. When does the fiscal year end for Adaptimmune Therapeutics?
Adaptimmune Therapeutics's fiscal year ends in December. Where is Adaptimmune Therapeutics based?
Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX What is Adaptimmune Therapeutics's ISIN number?
Adaptimmune Therapeutics's international securities identification number is: US00653A1079 What is Adaptimmune Therapeutics's CUSIP number?
Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107
More guides on Finder
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Ask an Expert